NO20000935D0 - Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei - Google Patents

Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Info

Publication number
NO20000935D0
NO20000935D0 NO20000935A NO20000935A NO20000935D0 NO 20000935 D0 NO20000935 D0 NO 20000935D0 NO 20000935 A NO20000935 A NO 20000935A NO 20000935 A NO20000935 A NO 20000935A NO 20000935 D0 NO20000935 D0 NO 20000935D0
Authority
NO
Norway
Prior art keywords
alternative pathway
complement activation
activation via
inhibiting complement
inhibiting
Prior art date
Application number
NO20000935A
Other languages
English (en)
Other versions
NO20000935L (no
Inventor
Rekha Gupta-Bansal
Kurt R Brunden
James B Parent
Original Assignee
Gliatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gliatech Inc filed Critical Gliatech Inc
Publication of NO20000935D0 publication Critical patent/NO20000935D0/no
Publication of NO20000935L publication Critical patent/NO20000935L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Cereal-Derived Products (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
NO20000935A 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei NO20000935L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91834997A 1997-08-26 1997-08-26
PCT/US1998/017500 WO1999010009A1 (en) 1997-08-26 1998-08-24 A process for inhibiting complement activation via the alternative pathway

Publications (2)

Publication Number Publication Date
NO20000935D0 true NO20000935D0 (no) 2000-02-25
NO20000935L NO20000935L (no) 2000-04-18

Family

ID=25440234

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000935A NO20000935L (no) 1997-08-26 2000-02-25 Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei

Country Status (13)

Country Link
US (3) US6333034B1 (no)
EP (1) EP1007092B1 (no)
JP (1) JP2001513576A (no)
AT (1) ATE335511T1 (no)
AU (1) AU756490B2 (no)
CA (1) CA2302317A1 (no)
DE (1) DE69835524T2 (no)
DK (1) DK1007092T3 (no)
ES (1) ES2270530T3 (no)
NO (1) NO20000935L (no)
NZ (1) NZ503033A (no)
PT (1) PT1007092E (no)
WO (1) WO1999010009A1 (no)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641571B2 (en) * 2000-01-05 2003-11-04 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Reduction of postoperative complications of cardiopulmonary bypass (CPB) surgery
ES2483991T3 (es) 2000-10-10 2014-08-08 Genentech, Inc. Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
CA2454562A1 (en) * 2001-07-26 2003-02-06 Alexion Pharmaceuticals, Inc. Method of improving cognitive function
ES2198216B1 (es) * 2002-07-02 2005-04-16 Juan Carlos Instituto Cientifico Y Tecnologico De Navarra, S.A.(67%). Medio de cultivo de celulas madre-progenitoras autologas humanas y sus aplicaciones.
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7361339B2 (en) * 2003-01-09 2008-04-22 Alexion Pharmaceuticals, Inc. Methods for reducing morality associated with acute myocardial infarction
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004103288A2 (en) * 2003-05-13 2004-12-02 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of preventing recurrent miscarriages
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
PT1713503E (pt) * 2004-02-10 2013-11-14 Nat Jewish Health Inibição do factor b, a via alternativa do complemento e métodos relacionados
EP1737487B1 (en) * 2004-03-30 2016-05-25 Canadian Blood Services Method for treating autoimmune diseases with antibodies
BRPI0401765C1 (pt) * 2004-05-17 2011-03-15 Hy Biotecnologica Ltda método de enriquecimento de espermatozoides de mamìferos portadores de cromossomo x ou de cromossomo y
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
CA2610340C (en) * 2005-05-26 2016-02-16 Vernon Michael Holers Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
AU2006311803C1 (en) * 2005-11-04 2015-05-14 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL2289909T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Sposób przeszukiwania, proces oczyszczania niedyfundujących oligomerów Abeta, selektywne przeciwciała przeciw niedyfundującym oligomerom Abeta i sposób wytwarzania tych przeciwciał
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
TWI391401B (zh) * 2006-11-02 2013-04-01 Genentech Inc 人類化之抗-因子ｄ抗體及其用途
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
EP2118142A2 (en) * 2007-03-14 2009-11-18 Taligen Therapeutics, Inc. Humaneered anti-factor b antibody
US9745367B2 (en) * 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
CN101932337A (zh) * 2007-06-11 2010-12-29 宾夕法尼亚大学董事会 替代途径的血清灭菌蛋白调节及其应用
EP2195024B1 (en) * 2007-08-27 2016-10-05 NovelMed Therapeutics, Inc. Method of inhibiting complement activation with factor bb specific antibodies
US10131706B2 (en) 2007-08-27 2018-11-20 Novelmed Therapeutics, Inc. Anti-factor Bb antibodies
US8435512B2 (en) 2008-03-03 2013-05-07 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US20140127204A1 (en) 2010-09-03 2014-05-08 Novelmed Therapeutics, Inc. Anti-properdin antibodies
US8664362B2 (en) 2008-03-03 2014-03-04 NovelMed Therapeutics Humanized and chimeric anti-properdin antibodies
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
US20110160636A1 (en) * 2008-09-10 2011-06-30 Rekha Bansal Device and method for inhibiting complement activation
WO2010057084A1 (en) * 2008-11-14 2010-05-20 Novelmed Therapeutics, Inc. Method of treating ischemia reperfusion injury
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
AU2011223660B2 (en) * 2010-03-02 2016-10-13 Novelmed Therapeutics, Inc. A method for inhibiting alternative pathway mediated disorders with anti-properdin antibodies that inhibit C5 interactions with properdin
CN103003302B (zh) * 2010-03-10 2015-09-30 诺沃姆德治疗公司 人源化和嵌合抗-备解素抗体
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103298833B (zh) 2010-08-14 2015-12-16 Abbvie公司 β淀粉样蛋白结合蛋白
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
JP6293659B2 (ja) 2011-07-01 2018-03-14 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗プロペルジン抗体およびその使用
ES2728278T3 (es) 2011-12-21 2019-10-23 Novartis Ag Composiciones que comprenden anticuerpos dirigidos al factor P y C5
CA2869477C (en) 2012-04-03 2020-06-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014055835A1 (en) 2012-10-04 2014-04-10 Novelmed Therapeutics, Inc. Alternative pathway specific antibodies for treating hemolytic diseases
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
KR20160042438A (ko) 2013-08-12 2016-04-19 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
PE20161440A1 (es) 2014-05-01 2017-01-26 Genentech Inc Variantes del anticuerpo anti-factor d y sus usos
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
CA3011819A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
EP3275897A1 (en) * 2016-07-27 2018-01-31 Biotest AG Process for preparing immunoglobulin compositions
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
US11981727B2 (en) 2021-08-31 2024-05-14 Novelmed Therapeutics, Inc Monospecific and bispecific antibodies and antigen binding fragments thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642284A (en) * 1983-06-13 1987-02-10 Scripps Clinic And Research Foundation Method and system for detection of complement pathway activation
US5434075A (en) * 1992-03-20 1995-07-18 Board Of Trustees Of The University Of Illinois Monoclonal antibody to a human MDR1 multidrug resistance gene product, and uses
ES2236706T3 (es) 1994-03-23 2005-07-16 Alexion Pharmaceuticals, Inc. Procedimiento para reducir las disfunciones de los sistemas inmunitario y hemostatico durante la circulacion extracorporal.

Also Published As

Publication number Publication date
NO20000935L (no) 2000-04-18
EP1007092A1 (en) 2000-06-14
DK1007092T3 (da) 2006-10-02
ATE335511T1 (de) 2006-09-15
AU9203398A (en) 1999-03-16
PT1007092E (pt) 2006-12-29
US6333034B1 (en) 2001-12-25
CA2302317A1 (en) 1999-03-04
EP1007092B1 (en) 2006-08-09
AU756490B2 (en) 2003-01-16
DE69835524D1 (de) 2006-09-21
US20020015701A1 (en) 2002-02-07
US20030198636A1 (en) 2003-10-23
DE69835524T2 (de) 2007-04-05
ES2270530T3 (es) 2007-04-01
JP2001513576A (ja) 2001-09-04
NZ503033A (en) 2003-01-31
WO1999010009A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
NO20000935L (no) Fremgangsmåte for inhibering av komplementaktivering via den alternative reaksjonsvei
PT841928E (pt) Formulacao de libertacao prolongada de d-trep-metilfenidato
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
FI980862A0 (fi) Kiraalisia metyylifenyylioksatsolidinoneja
BG102474A (en) (-)-cis-6(s)-phenyl-5(r)-[4-(2-pyrrolidine-1-yletoxi)phenyl)-5,6,7 ,8-tetrahydronaphthalen-2-ol-d-tartarate
BR9612297A (pt) Método de produção de 1,1,1,3,3-pentafluorpropano
ATE180776T1 (de) Naphthylverbindungen, zwischenprodukte, zusammensetzungen und methoden
NO961483L (no) Fremgangsmåte for behandling av oljeholdig formasjon
MX9605206A (es) 1alfa,26-dihidroxi-d-homo-vitamina d3.
NO971645D0 (no) Fremgangsmåte for fremstilling av derivater av 4a,5,9,10,11,12,-heksahydro-6H-benzofuro(3a,3,2-ef)(2)-benzacepin
NO981800L (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
TR199601005A2 (tr) Uzun zincirli, dallanmis poliolefinlerin üretimi icin yöntem.
AU2895397A (en) Novel substance library and supramolecular complexes prepared therewith
YU12000A (sh) Supstituisani 1,2,3,4,5,6-heksahidro-2,6-metano-3-benzazocin -10-oli, postupak za njihovo pripremanje i njihova primena kao lekova
BG103649A (en) Method for the preparation of eprosartan
MX9706744A (es) Proceso novedosos para preparar derivados de 2,3-dihidro-benzofuranol.
BG103650A (en) Method for the preparation of eprosartan
NO990450D0 (no) Behandling av sinnslidelser
DK0735043T3 (da) Fremgangsmåde til fremstilling af 2-substitueret 3,3-difluorfuran
ZA995559B (en) Improved process for the production of an n-acyl derivative of O,S-dialkyl phosphoroamidothioate.
NO975582L (no) Fremgangsmåte for syntese av benzo£b|tiofener
MX9604599A (es) Procedimiento para la sintesis enzimatica de nucleotido-6-desoxi-d-xilo-4-hexulosas.
NO950015D0 (no) Liposomer, anvendelige som jernkilde, samt fremgangsmåte for fremstilling av slike liposomer
MX9606264A (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol como sustancias farmacologicas activas.
GR950200227U (en) Method and machine for the production of asphalt-mixture.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application